Floatz logo

Paliperidone Palmitate 3-Month Formulation

Antipsychotic Agents

Centre for Addiction and Mental HealthPhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Antipsychotic Agents cohort.

Asset / SponsorPhaseRating
Olanzapine
Centre for Addiction and Mental Health
Phase 4BB
Risperdal
Centre for Addiction and Mental Health
Phase 4BB
2-TRIFLUOROMETHYL-9-(3-(4-(2-HYDROXYETHYL)PIPERAZIN-1-YL)PROPYLIDENE)THIOXANTHENE
Taichung Veterans General Hospital
Phase 4B
ly03010
Luye Pharma Group Ltd.
Phase 1CCC

Same molecule, other indications

Paliperidone Palmitate 3-Month Formulation is also rated in:

schizoaffective disorderDormant
BBB
Indicative ·
78 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
76 / 100
View asset →
schizophreniaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →